Search Results for “EC” – Page 547 – media

ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes

First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.
- Source: Pipelinereview
- 509
- April 13, 2018
New Approvals type 2 diabetes
Magenta bags $52M Series C for bone marrow transplant pipeline

High-flying Cambridge startup Magenta has snagged $52 million in a new financing round to push forward the company’s pipeline of therapies for bone marrow transplant.
- Source: Endpts
- 469
- April 13, 2018
financing Market Views
Bristol-Myers Squibb and Harvard Announce New Fibrosis Research Collaboration

Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute today announce a research collaboration to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University.
- Source: news.bms
- 594
- April 13, 2018
Bristol-Myers Squibb fibrotic diseases
Blockchain System Aims to Identify Health Problems Using AI

A new Blockchain platform has seemingly proven that it is possible to for AI to perform more accurate health diagnosis than human doctors, paving the way for a change in the way medical tests are performed.
- Source: Cointelegraph
- 657
- April 12, 2018
AI digital health Market Views
Cleveland Clinic Targets Telemedicine, Big Data and AI to Improve the Future of Care

The healthcare leader relies on digital platforms, a closer relationship with IBM to continue to fast-forward care.
- Source: HealthTech Magazine
- 623
- April 12, 2018
digital health health IT Researches
FDA Prolongs Review Date for AbbVie Endometriosis Candidate

The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.
- Source: finance.yahoo
- 534
- April 12, 2018
elagolix endometriosis New Approvals
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication.
- Source: Illumina
- 496
- April 12, 2018
larotrectinib Market Views
Alexion to buy Wilson for $855m

Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million. Wilson is a Swedish biopharma developing novel therapies for patients with rare copper-mediated disorders.
- Source: pharmatimes
- 470
- April 12, 2018
Alexion Market Views rare copper-mediated disorders
Novartis’ Afinitor Disperz wins new TSC-related approval

Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
- Source: pharmatimes
- 731
- April 12, 2018
Afinitor Disperz New Approvals Novartis TSC
FDA restricts sales of a Bayer’s Essure birth control device

The Food and Drug Administration(FDA) moved Monday to put sales restrictions on a Bayer birth control implant that has been a target of consumer criticism.
- Source: Usatoday
- 505
- April 11, 2018
Company Insights contraceptive device

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.